Brain FGF2 and NCAM1 contribute to FGFR1-dependent progression of estrogen receptor-positive breast cancer brain metastases.
Overview
- Department of Pathology, University of Colorado Anschutz,Aurora, CO USA
- Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz,Aurora, CO USA
- University of Colorado Comprehensive Cancer Center, University of Colorado Anschutz,Aurora, CO USA
- Department of Radiology, University of Colorado Anschutz,Aurora, CO USA
- Department of Pathology, University of Oklahoma Health Sciences Center,Oklahoma City, OK USA
- Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center,Oklahoma City, OK USA
- Stephenson Cancer Center, University of Oklahoma Health Sciences Center,Oklahoma City, OK USA
Abstract
Estrogen receptor-positive breast cancer represents a significant proportion of breast cancer brain metastasis but remains understudied. Here we show that FGFR1-amplification, a well-established driver of estrogen receptor-positive breast cancer endocrine resistance, promotes estrogen receptor-positive breast cancer brain metastatic colonization in young and aged female mice, through both canonical FGF2/
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data and to no code of its authors: see the Data section.
Code availability
All information is provided in the Methods, including packages, software, and pipelines. No custom code was generated during these studies.
Reproduced under the paper's license (CC BY), from the paper cited above.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- geo:GSE301400, at NCBI GEO; found in “Data availability”
Data availability
The Digital Spatial Profiling and RNA-sequencing data generated in this study have been deposited in the NCBI’s Gene Expression Omnibus under accession codes GSE301400 (https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 28 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 13 authors, 3 keywords, 18 MeSH terms, 2 funders, 80 references, 3 RRIDs.
Cite
This paper
Fox, M. S., Jaramillo-Gómez, J. A., Marquez-Ortiz, R. A., Alvarez-Eraso, K. L. F., Contreras-Zárate, M. J., Pham, T. C., Barela, E. N., Koliavas, S. N., Kabos, P., Serkova, N. J., Sartorius, C. A., Wellberg, E. A., & Cittelly, D. M. (2026). Brain FGF2 and NCAM1 contribute to FGFR1-dependent progression of estrogen receptor-positive breast cancer brain metastases. Nature communications, 17(1), 6945. https://
BibTeX
@article{fox2026brain,
author = {Fox, Morgan S. and Jaramillo-Gómez, Jenny A. and Marquez-Ortiz, R. Alejandro and Alvarez-Eraso, Karen L. F. and Contreras-Zárate, Maria J. and Pham, Trinh C. and Barela, Elaina N. and Koliavas, Stella N. and Kabos, Peter and Serkova, Natalie J. and Sartorius, Carol A. and Wellberg, Elizabeth A. and Cittelly, Diana M.},
title = {{Brain FGF2 and NCAM1 contribute to FGFR1-dependent progression of estrogen receptor-positive breast cancer brain metastases}},
journal = {Nature communications},
year = {2026},
month = may,
volume = {17},
number = {1},
pages = {6945},
publisher = {Nature Publishing Group},
issn = {2041-1723},
doi = {10.1038/
url = {https://
pmid = {42209519},
pmcid = {PMC13388965}
}
RIS
TY - JOUR
AU - Fox, Morgan S.
AU - Jaramillo-Gómez, Jenny A.
AU - Marquez-Ortiz, R. Alejandro
AU - Alvarez-Eraso, Karen L. F.
AU - Contreras-Zárate, Maria J.
AU - Pham, Trinh C.
AU - Barela, Elaina N.
AU - Koliavas, Stella N.
AU - Kabos, Peter
AU - Serkova, Natalie J.
AU - Sartorius, Carol A.
AU - Wellberg, Elizabeth A.
AU - Cittelly, Diana M.
TI - Brain FGF2 and NCAM1 contribute to FGFR1-dependent progression of estrogen receptor-positive breast cancer brain metastases
T2 - Nature communications
J2 - Nat Commun
PY - 2026
DA - 2026/
VL - 17
IS - 1
SP - 6945
SN - 2041-1723
PB - Nature Publishing Group
DO - 10.1038/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1038/
"type": "article-journal",
"title": "Brain FGF2 and NCAM1 contribute to FGFR1-dependent progression of estrogen receptor-positive breast cancer brain metastases",
"container-title": "Nature communications",
"author": [
{
"family": "Fox",
"given": "Morgan S."
},
{
"family": "Jaramillo-Gómez",
"given": "Jenny A."
},
{
"family": "Marquez-Ortiz",
"given": "R. Alejandro"
},
{
"family": "Alvarez-Eraso",
"given": "Karen L. F."
},
{
"family": "Contreras-Zárate",
"given": "Maria J."
},
{
"family": "Pham",
"given": "Trinh C."
},
{
"family": "Barela",
"given": "Elaina N."
},
{
"family": "Koliavas",
"given": "Stella N."
},
{
"family": "Kabos",
"given": "Peter"
},
{
"family": "Serkova",
"given": "Natalie J."
},
{
"family": "Sartorius",
"given": "Carol A."
},
{
"family": "Wellberg",
"given": "Elizabeth A."
},
{
"family": "Cittelly",
"given": "Diana M."
}
],
"container-title-short":
"volume": "17",
"issue": "1",
"page": "6945",
"DOI": "10.1038/
"PMID": "42209519",
"PMCID": "PMC13388965",
"ISSN": "2041-1723",
"publisher": "Nature Publishing Group",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
5,
28
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1158/2767-9764.crc-25-0811
- Targeting Wild-type NTRK in NTRK Fusion-Negative Lung Cancer Decreases Brain Metastases.Journal: Cancer research communicationsIn common: other condition, mouse, cellular / molecular, 5 references, 4 authors
- [2] doi:10.1038/s41467-026-72927-2
- Complex I protein NDUFB9 is a metabolic vulnerability in triple negative breast cancer brain metastases.Journal: Nature communicationsIn common: other condition, mouse, cellular / molecular, 5 references
- [3] doi:10.64898/2025.12.10.693579 [code]
- Serotonergic neuron-glioma interactions drive high-grade glioma pathophysiologyJournal: bioRxiv (preprint)In common: other condition, cellular / molecular, 4 references
- [4] doi:10.1038/s41467-025-64937-3
- Transcriptional regulation of protein synthesis by mediator kinase represents a therapeutic vulnerability in MYC-driven medulloblastoma.Journal: Nature communicationsIn common: other condition, mouse, cellular / molecular, author Natalie J. Serkova
- [5] doi:10.1016/j.ccell.2023.07.010 [code]
- Machine learning identifies experimental brain metastasis subtypes based on their influence on neural circuits.Journal: Cancer cellIn common: other condition, 5 references
- [6] doi:10.1186/s43556-025-00251-0
- Cancer brain metastasis: molecular mechanisms and therapeutic strategies.Journal: Molecular biomedicineIn common: other condition, 4 references
- [7] doi:10.15252/emmm.202216111
- Synaptogenic gene therapy with FGF22 improves circuit plasticity and functional recovery following spinal cord injury.Journal: EMBO molecular medicineIn common: other condition, cellular / molecular, 3 references
- [8] doi:10.1038/s41467-023-38252-8
- Type I interferon response in astrocytes promotes brain metastasis by enhancing monocytic myeloid cell recruitment.Journal: Nature communicationsIn common: other condition, cellular / molecular, 4 references
- [9] doi:10.1073/pnas.2322688121
- Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies.Journal: Proceedings of the National Academy of Sciences of the United States of AmericaIn common: other condition, mouse, 4 references
- [10] doi:10.1038/s41467-025-66226-5 [code]
- Aberrant neural activity in the peritumoral cortex underlies the progression of tumor-associated seizures.Journal: Nature communicationsIn common: other condition, mouse, cellular / molecular, 4 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
